Advantages and perspectives of using medicines in the form of auto injectors and prefilled syringes
Today, there is a need to introduce medical devices into everyday medical practice with the goal to self-administer injectional drugs. The speed and safety of auto-injectors / pre-filled syringe pens use (AI/PFS) is the introduction of an injectional form drug in a special medical device, which allows patients to enter a pre-designated therapeutic dose due to the characteristics of the structure of the product, automatic dosing, data of the interactive display on some devices, comfortable design, etc. Considering that AI/PFS were developed to improve the quality of life of patients with various pathological conditions, therefore the creation of affordable medical devices for low-income groups of the population is relevant today. Also an actual issue is the provision of high-quality first-aid kits for soldiers, which is a vital component for medical care in the context of active combat conditions and the lack of the required number of field hospitals.The speed of administration, the onset of effect and ease of use provides significant advantages for AI / PFS. Therefore, the issue of affordability for the low-income groups of the population and the army with the necessary drugs should be sufficiently supported by state regulation.Purpose of study – study of the international experience in the implementation and use of drugs (drugs) in the form of affordable, safe and effective modern dosage forms in the form of autoinjectors.Materials and methods – foreign and domestic literature on the use of AI/PFS in complex and monotherapy treatment of various diseases. State registries of medicines of Ukraine, the USA and some EU countries. The study used systematic, statistical and comparative analyzes, as well as the generalization of information. The data used is freely available among various medical scientific and metric bases, the Internet and international scientific conferences.The analysis of the use of AI/PFS indicates that today the world market of medicines and medical devices contains a large number of drugs under different trade names. However, many patients in the world refrain from using these dosage forms due to the significant cost of medical devices, which makes impossible the required regular use of such drugs for the low-income population groups. This is a significant disadvantage, since AI / PFS is implemented to correct not only chronic diseases such as rheumatoid arthritis, multiple sclerosis, but also to provide emergency careinurgent conditions (anaphylactic reactions, intense pain, etc.).In the global market for drugs and medical devices, injectable medicines in the form of AI/PFS are widely represented. The effectiveness of the use of such devices indicates the advantages and prospects for the use of existing AI/PFS on the global market for patients and medical personnel. Today, the most commonly used drugs in AI/PFSare for the treatment of diabetes, emergency conditions in civil and military medicine, chronic diseases of various etiologies, pediatric practice. The use of AI /PFS significantly improves patient compliance for the treatment of chronic diseases due to ease of use and reduction of adverse reactions at the site of administration. Most of the analyzed sources indicate a low level of economic affordability of drugs in the form of AI/PFS for the population and the government sector of drug supply due to the high cost of the medical devices, compared to traditional syringes. But the results of the study indicate a high level of advantages and prospects in the use of drugs in AI/PFS in medical practice for both medical personnel and patients.
2. Masid M. L., Ocaña R. H., Gil M. J. et al. A patient care program for adjusting the autoinjector needle depth according to subcutaneous tissue thickness in patients with multiple sclerosis receiving subcutaneous injections of glatiramer acetate // J. Neurosci. Nurs. – 2015. – V. 47, N 1. – P. 22−30. https://doi.org/10.1097/JNN.0000000000000086
3. Gudiksen N., Hofstätter T., Rønn B. B., Sparre T. FlexTouch: An insulin pen-injector with a low activation force across different insulin formulations, needle technologies, and temperature conditions // Diabetes Technol. Ther. – 2017. – V. 19, N 10. – P. 603−607. https://doi.org/10.1089/dia.2017.0121
4. Lange J., Urbanek L., Burren S. Development of devices for self-injection: using tribological analysis to optimize injection force // Med. Devices (Auckl). – 2016. – V. 9. – P. 93−103. https://doi.org/10.2147/MDER.S106675
5. Limmroth V., Reischl J., Mann B. et al. Autoinjector preference among patients with multiple sclerosis: results from a national survey // Patient Prefer. Adherence. – 2017. − V. 11. − P. 1325−1334. https://doi.org/10.2147/PPA.S137741
6. Barrow-Williams T., Burnell R. Auto-injectors: technology advances and market trends // Innovations and pharmaceutical technology. – 2007. − N 23. − P. 57−62.
7. Asch D., Pfeifer K. E., Arango J. et al. Journal club: Benefit of epinephrine autoinjector for treatment of contrast reactions: comparison of errors, administration times, and provider preferences // AJR Am. J. Roentgenol. 2017. V. 209, N 2. Р. 363369. https://doi.org/10.2214/ajr.16.17111
8. Shin D., Lee Y., Jeong D., Ellis-Pegler R. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects // Drug. Des. Devel. Ther. 2018. V. 12. P. 37993805. https://doi.org/10.2147/dddt.s169082
9. Adrenaline auto-injectors: a review of clinical and quality considerations / Medicines and Healthcare Products Regulatory Agency (MHRA). – 2014. – 33 p. – Режим доступу: http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con423091.pdf
10. Kim L., Nevis I. F., Tsai G. et al. Children under 15 kg with food allergy may be at risk of having epinephrine auto-injectors administered into bone // Allergy Asthma Clin. Immunol. – 2014. − V. 10, N 1. – P. 40. https://doi.org/10.1186/1710-1492-10-40
11. Abrams E. M., Singer A. G., Lix L. et al. Adherence with epinephrine autoinjector prescriptions in primary care // Allergy Asthma Clin. Immunol. – 2017. – V. 13. – P. 46. https://doi.org/10.1186/s13223-017-0218-5
12. Kleiter I., Lang M., Jeske J. et al. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study // BMC Neurol. – 2017. – V. 17, N 1. – P. 174. https://doi.org/10.1186/s12883-017-0953-8
13. Hudry C., Lebrun A., Moura B. et al. Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis // Rheumatol. Ther. – 2017. − V. 4, N 1. – P. 183−194. https://doi.org/10.1007/s40744-017-0057-3
14. Schiff M., Jaffe J., Freundlich B., Madsen P. New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis // Expert. Rev. Med. Devices. 2014. V. 11, N 5. Р. 447455. https://doi.org/10.1586/17434440.2014.929492
15. Merlin M. A., Ariyaprakai N., Arshad F. H. Assessment of the safety and ease of use of the naloxone auto-injector for the reversal of opioid overdose // Open Access Emerg. Med. – 2015. − V. 7. – P. 21−24. https://doi.org/10.2147/oaem.s82133
16. Gottlieb A.B., Blauvelt A., Prinz J.C. et al. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: results of the FEATURE trial // J. Drugs. Dermatol. 2016. V. 15, N 10. Р. 12261234.
17. Truong T. H., Nguyen T. T., Armor B. L., Farley J. R. Errors in the Administration Technique of Insulin Pen Devices: A Result of Insufficient Education // Diabetes Ther. – 2017. – V. 8, N 2. – P. 221−226. https://doi.org/10.1007/s13300-017-0242-y
18. Vlasenko I. O., Davtian L. L., Zhohov I. V. Cuchasni prylady dlia samokontroliu tsukrovoho diabetu // Dyabet. Ozhyrenye. Metabolycheskyi syndrom. – 2013. – N 4. – P. 7–15.
19. Grissinger M. "Wrong Patient" Insulin Pen Injections Alarmingly Frequent Even With Barcode Scanning // P T. – 2017. – V. 42, N 9. – P. 550−552, p. 550.
20. Moshiri M., Darchini-Maragheh E., Balali-Mood M. Advances in toxicology and medical treatment of chemical warfare nerve agents // Daru. – 2012. – V. 20, N 1. – Р. 81. https://doi.org/10.1186/2008-2231-20-81
21. STANAG 2871 CBRNMED (edition 4) – first-aid materiel for chemical injuries / Military committee medical standardization board (MCMedSB). – 2009 [Електронний ресурс]. – Режим доступу: https://www.shape.nato.int/resources/site6362/medica-secure/publications/stanag%202871%20ed04.pdf]
22. Vijayaraghavan R. Autoinjector device for rapid administration of life saving drugs in emergency (review paper) // Defence sci. j. – 2012. − V. 62, N 5. − P. 307–304. https://doi.org/10.14429/dsj.62.2317
23. Wright C. Battlefield administration of tranexamic acid by combat troops: a feasibility analysis // J. r. army med. corps. – 2014. − V. 160, N 4. – P. 271−272. https://doi.org/10.1136/jramc-2013-000152
24. Bilous M. V., Shmatenko O. P., Ryzhov O. A., Drozdov D. V. Osnovni aspekty medychnoho postachannia u zbroinykh sylakh derzhav-chleniv NATO // Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky. – 2016. – V. 2, N 21. – P. 102–109.
25. Nakaz MOZ vid 05. 01. 2017 № 6 «Pro zatverdzhennia perelikiv likarskykh zasobiv ta medychnykh vyrobiv, yaki povynni buty v skladi aptechok medychnykh zahalnoviiskovykh indyvidualnykh, aptechky avtomobilnoi zahalnoviiskovoi, naplichnyka medychnoho zahalnoviiskovoho sanitara ta naplichnyka medychnoho zahalnoviiskovoho sanitarnoho instruktora». Retrieved from http://zakon.rada.gov.ua/laws/show/z0113-17#n17
26. Westermann-Clark E., Pepper A. N., Lockey R. F. Westermann-Clark E. Economic considerations in the treatment of systemic allergic reactions // J. Asthma Allergy. 2018. V. 11. P. 153158. https://doi.org/10.2147/jaa.s159851
27. Armstrong N., Wolff R., van Mastrigt G. et al. A systematic review and cost-effectiveness analysis of specialist services and adrenaline auto-injectors in anaphylaxis // Health Technol Assess. – 2013. – V. 17, N 17. – P. 1−117
28. Dorovskyi O. V., Yaroshenko I. V. () Porivnialna kharakterystyka farmatsevtychnykh rynkiv krain YeS i SND // Biznesinform. – 2014. – N 12. – P. 47–61.
29. Krehan V. Novyie perspektivyi v Rossii dlya predvaritelno zapolnyaemyih shpritsov dlya in'ektsiy biotehnologicheskih preparatov. – 2012. – Retrieved from http://www.pharmtech-expo.ru/www_pharmtech/files/f4/f442867d-f6c7-49f2-a8d2-1d297e7b17d5.pdf
30. HPR volume 12 issue 42: news (23 November). 2018. Retrieved from https://www.gov.uk/government/publications/health-protection-report-volume-12-2018/hpr-volume-12-issue-42-news-23-november#infections-among-people-who-inject-drugs-in-the-uk-annual-report-in-summary
31. Chime N. O., Riese V. G., Scherzer D. J. et al. Epinephrine auto-injector versus drawn up epinephrine for anaphylaxis management: a scoping review // Pediatr Crit Care Med. 2017. V. 18, N 8. Р. 764769. https://doi.org/10.1097/PCC.0000000000001197
32. Thomson H., Seith R., Craig S. Downstream consequences of diagnostic error in pediatric anaphylaxis // BMC Pediatr. 2018. V. 18, N 1. P. 40. https://doi.org/10.1186/s12887-018-1024-z
33. Tischer B., Mehl A. Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey // Patient Prefer Adherence. 2018. V. 12. P. 14131424. https://doi.org/10.2147/PPA.S169339
34. Neborachko M., Pkhakadze A., Vlasenko I. Current trends of digital solutions for diabetes management Diabetes & Metabolic Syndrome: Clinical Research & Reviews. – 2018. – V. 12, Issue 4. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S1871402118303266#. https://doi.org/10.1016/j.dsx.2018.07.014
This work is licensed under a Creative Commons Attribution 4.0 International License.